Inovio Pharmaceuticals, Inc.

As of June 30, 2026, Inovio Pharmaceuticals, Inc. carries a market capitalization of 1.69B, placing it among publicly traded companies globally. Its enterprise value stands at 1.19B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Inovio Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for November 10, 2026.

As of June 30, 2026, Inovio Pharmaceuticals, Inc. has 82.34M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Inovio Pharmaceuticals, Inc. maintains a current ratio of 1.00, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Inovio Pharmaceuticals, Inc. posted a negative return on equity (ROE) of -409.87, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -114.64, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 117.50, a quick read on workforce productivity versus industry peers.

As of the close on October 21, 2026, Inovio Pharmaceuticals, Inc.'s stock has declined approximately 67.19% over the past 52 weeks. The 50-day moving average sits at 30.69, while the 200-day moving average is 95.29.

Over the twelve months ended June 30, 2026, Inovio Pharmaceuticals, Inc. generated - - in revenue and converted that into -1.18B in net income, yielding earnings per share of -17.33. EBITDA reached -1.33B, while operating income came in at -1.38B.

As of June 30, 2026, Inovio Pharmaceuticals, Inc. holds 640.75M in cash and equivalents against 139.81M in total debt, resulting in a net debt position of -550.81M. Total book value stands at 76.37M, with working capital of -31,623.60 providing operational flexibility.

Inovio Pharmaceuticals, Inc. produced -1.41B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -3.41M in capital expenditures, free cash flow totaled -1.41B - equivalent to -20.76 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -101.13: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -72.52, meaning Inovio Pharmaceuticals, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Inovio Pharmaceuticals, Inc.'s most recent stock split took place on January 26, 2024 with a 12:1 split ratio.

As of June 30, 2026, Inovio Pharmaceuticals, Inc. has an Altman Z-Score of -56.19, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.